Pantoprazole is Superior to Ranitidine in the Treatment of Acute Gastric Ulcer

Hotz, J; Plein, K.; Schönekäs, H; Rose, Kyle Jacques

doi:10.3109/00365529509093247

Cited by 15 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pantoprazole has been extensively studied in clinical trials in Europe and other countries for the prevention and healing of gastric and duodenal ulcers and symptomatic and erosive gastro‐oesophageal reflux disease oesophagitis 7–13 . It has also demonstrated efficacy and safety in the maintenance treatment of gastro‐oesophageal reflux disease, with a duration of treatment for up to 3 years 14 , .…”

Section: Introductionmentioning

confidence: 99%

Dose‐dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers

Tutuian

Katz

Bochenek

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Proton pump inhibitors have emerged as the most effective class of drugs for the treatment of gastro‐oesophageal reflux. Pantoprazole is a proton pump inhibitor that has demonstrated high clinical efficacy. Aim: To evaluate the effect of once‐daily doses of pantoprazole, 10, 20 and 40 mg, on gastric acidity in healthy volunteers. Methods: Thirty‐six subjects received pantoprazole in a three‐way crossover design study. Ambulatory 24‐h intragastric pH and distal oesophageal pH were monitored at baseline and on the last day of each treatment period. The measured endpoints were the median intragastric and oesophageal pH, the percentage of time the intragastric pH < 4 and oesophageal pH < 4 and the area under the curve for gastric acidity over 24 h. Safety was evaluated by incidence and severity of adverse events. Results: Pantoprazole demonstrated a linear dose‐ dependent suppression of gastric acidity over the dose range 10–40 mg. The dose of 40 mg demonstrated a significantly greater response than the lower doses, particularly at night. All pantoprazole doses were well tolerated. Conclusions: Pantoprazole demonstrates a dose‐related effect in the range 10–40 mg once daily. The once‐daily dose of 40 mg provides the highest and most consistent control of gastric pH, especially at night.

show abstract

Section: Introductionmentioning

confidence: 99%

Dose‐dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers

Tutuian

Katz

Bochenek

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In a study of 243 patients, omeprazole 20 mg once daily and pantoprazole 40 mg daily resulted in 8 week healing rates of 96-97% [57]. In another study, healing with pantoprazole 40 mg was clearly superior to ranitidine 300 mg at 2 weeks (37 vs 19%), 4 weeks (87 vs 58%) and 8 weeks (97 vs 80%) [58]. As with DUs, there have been few comparative studies done between PPIs in GUs.…”

Section: Duodenal and Gastric Ulcersmentioning

confidence: 94%

Pantoprazole: a proton pump inhibitor with oral and intravenous formulations

DeVault¹

2007

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Proton pump inhibitors (PPI) are a significant part of therapy for most acid-related diseases including gastroesophageal reflux disease, peptic ulcer disease and acute gastrointestinal bleeding. Pantoprazole is one of several available proton pump inhibitor agents and provides dose-dependent control of gastric acid secretion. Pantoprazole has indications in gastroesophageal reflux disease and peptic ulcer disease, along with indications as co-therapy in the eradication of Helicobacter pylori infection and in the control of the acid secretion associated with the Zollinger-Ellison syndrome, as well as in NSAID ulcer prevention. Pantoprazole is available in both oral and intravenous formulations. It is effective across all age groups, although only indicated in adults (and adolescents in Europe). It has been approved for use in over 100 countries and has been used for over 13 years. Pantoprazole has an excellent safety profile and a low potential for drug-drug interactions. While still widely prescribed, pantoprazole and the other branded proton pump inhibitors are under considerable market pressure from the less expensive but similarly effective generic and over-the-counter formulations of omeprazole.

show abstract

“…In a randomised, double-blind comparison involving 248 patients, pantoprazole 40mg daily was more effective than ranitidine 300mg daily 12. At 4 weeks, gastric ulcers had healed in 87% of patients on pantoprazole and 58% on ranitidine; at 8 weeks, healing had occurred in 97% of those on pantoprazole and 80% of those on ranitidine (p<.001) (per protocol analysis only reported).…”

Section: Clinical Studiesmentioning

confidence: 95%

▼Pantoprazole - a third proton pump inhibitor

1997

DTB

View full text Add to dashboard Cite

Pantoprazole (Protium - Knoll) is the third proton pump inhibitor to be marketed in the UK. It is licensed for the treatment of duodenal ulcer, benign gastric ulcer and reflux oesophagitis. Unlike omeprazole and lansoprazole, pantoprazole is not licensed for maintenance therapy in these disorders nor for use in the treatment of Helicobacter pylori infection. The manufacturer claims that pantoprazole offers "precise control in acid-related disorders", with "selective targeting" of the proton pump, "predictable pharmacokinetics" and minimal risk of interactions with other drugs. Does pantoprazole offer any advantage over established proton pump inhibitors?

show abstract

Pantoprazole is Superior to Ranitidine in the Treatment of Acute Gastric Ulcer

Abstract: Pantoprazole appears to be superior to ranitidine in gastric ulcer healing.

Cited by 15 publications

References 14 publications

Dose‐dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers

Dose‐dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers

Pantoprazole: a proton pump inhibitor with oral and intravenous formulations

▼Pantoprazole - a third proton pump inhibitor

Contact Info

Product

Resources

About